The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.

The first commercial priority for a clinical-stage biotech should be payer and health economics (HEOR) research. This ensures the clinical trial includes endpoints that demonstrate clear value to payers, which is essential for future reimbursement and market access.

There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

Paradromics' founder notes that while the FDA is collaborative, the slower, understaffed CMS, which determines reimbursement for Medicare/Medicaid patients, is the primary bottleneck. Gaining its approval is critical for market access, as private insurers often follow its lead.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.

Successfully launching in the U.S. market starts long before regulatory approval. Startups must pre-emptively map the entire adoption ecosystem—from patients to providers to clinicians—and develop tailored messaging for each stakeholder's unique priorities.

Even after proving a device works, getting FDA clearance, and securing a reimbursement code, investors' final question is about market traction. They want to see revenue before funding the sales team required to generate it, creating a final catch-22.

Don't wait until after FDA approval to think about reimbursement. Smart biotechs engage with payers early and build payer-valued outcomes directly into Phase 2/3 trials. This creates a ready-made value dossier for payers alongside the regulatory submission package.